The Stent, the Suture Line, and the Culture Nobody Was Chasing
A living-donor recipient's ureteral stent is due for its scheduled removal, but a tense anastomosis and an asymptomatic positive culture pull the team in opposite directions on how long the stent should stay — and whether the culture should be treated at all.
R.A., a 38-year-old shop teacher and his high school's assistant wrestling coach, spent nine years on hemodialysis after IgA nephropathy took his native kidneys in his twenties, and two weeks ago received a living-donor transplant from his younger sister — a decision the two of them had discussed since before he ever started dialysis. He went into surgery otherwise healthy: no diabetes, no prior abdominal operations, no history of urologic disease of his own that might have complicated the transplant plumbing. The graft has worked well from day one, his creatinine falling from a dialysis-dependent 8.1 to 1.3 by discharge and holding there since. The one wrinkle from the operating room was technical rather than immunologic: his sister's ureter ran shorter than the team expected once she was on the table, and the ureteroneocystostomy was completed under measurably more tension than the surgeon's own usual closures — a detail the operative note flagged on its own initiative, in real time, rather than one anyone is reading into after the fact.
At his post-operative day 10 visit — a routine surveillance culture obtained precisely because the double-J stent bridging that anastomosis is still in place — his urine grew E. coli at 100,000 CFU/mL, the same quantitative threshold Antonio and colleagues used to define treatable bacteriuria in their own 2022 controlled trial of exactly this early post-transplant window, which drew its own cultures at catheter removal, at week three, and again before stent removal. R.A. feels fine: no fever, no flank pain, no dysuria, voiding comfortably around the stent the way most patients do at this stage. The stent itself was scheduled for removal at three weeks under the unit's protocol, adopted only after the 2017 Patel trial and the Visser et al. 2019 meta-analysis built on it showed earlier removal, inside three weeks, cuts urinary tract infection without raising the rate of leaks or ureteral stenosis across more than a thousand pooled patients — a protocol built for a routine anastomosis, not written with an explicit carve-out for one completed under extra tension. Two questions are now sitting in the same visit rather than one: whether his stent should still come out on the schedule that protocol assumes, and whether a culture with no symptoms attached to it needs treating at all before that decision is even made.
Rounds, ten days after a tense anastomosis
Pull the stent at three weeks as planned. Patel's randomized trial and the Visser et al. 2019 meta-analysis built on it — pooling well over a thousand kidney transplant recipients — found early removal, inside three weeks, cut urinary tract infections without a corresponding rise in leaks, obstruction, or stenosis. That's not a marginal finding; it's consistent across every one of the pooled trials.
I understand the instinct to treat a tense closure as its own category. But 'the note mentions tension' isn't the same evidence as 'this anastomosis has a higher measured leak rate' — and extending stent time has its own real cost, which is exactly the infection risk we adopted early removal to avoid.
I'm not disputing the trial data in general — I'd pull most stents at three weeks without a second thought. But I was the one holding the needle when that ureter came up short, and I wrote the tension into the note because I wanted it on the record, not because I was being cautious for its own sake.
Saying the trial found no rise in leaks 'across the pooled population' doesn't tell me where a tense anastomosis specifically sits inside that population — most of those anastomoses weren't done under this much tension. Two extra weeks, not six, is a bounded, reversible hedge against a real technical finding, not a rejection of the trial.
Whichever way the stent question lands, don't touch the culture. Antonio and colleagues randomized patients with exactly this picture — asymptomatic bacteriuria, catheter or stent still in place, inside the first two months post-transplant — and found treating it changed nothing about the rate of symptomatic UTI or graft pyelonephritis.
R.A. is not an approximate match to that population; he is inside it on every axis that trial defined. Starting ciprofloxacin now buys nothing the data promises and adds real resistance pressure in a patient who will need antibiotics again, for something that actually matters, before this year is over.
Agreed: the stent comes out at three and a half weeks rather than the standard three — a short, explicitly bounded extension the surgical team requested in view of the documented anastomotic tension, not a return to the unit's older six-week practice. The asymptomatic culture is not treated; a single dose of cefazolin will be given at the time of removal itself, targeting the instrumentation, not the colonized urine sitting there now.
Not agreed, and left honestly open: how much a surgeon's own intraoperative impression of tension should weigh against a randomized population that never measured tension directly. Nobody on the team can say with real precision whether three and a half weeks is the right number or simply a number everyone could accept — the trials this decision leans on don't have an arm for this.